u/britt_okwuosa

I would not draw a trend line through that. Two points and a gap is not a series.

Lyophilisation removes the water that drives most degradation pathways. That is why the dry cake is comparatively robust and the reconstituted solution is not.

Same experience with the appetite effect being flatter across the week rather than front-loaded.

Attribution requires that one thing change at a time. A log with dose, training and intake all moving in the same fortnight cannot assign anything to any of them.

Push back: "gentler than sema" is a population statement.

Saving this one. It is the clearest statement of the stall problem I have read here.

Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

Once in solution, the relevant risks are hydrolysis, aggregation and, for some sequences, oxidation. Refrigeration slows all three; freezing a solution introduces a separate risk at the ice interface.

Cosigning the regional stock point. Ordering from a warehouse in Ireland took the whole question off my table.

Cosigning on missed weeks. Leaving them blank makes the whole series misleading.

Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.

This is the framing the board needs. It is a hepatic programme first.

Careful. "The cold chain failed" is a strong claim and the evidence you have is a warm box.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your early fullness pattern is a guess.

Once in solution, the relevant risks are hydrolysis, aggregation and, for some sequences, oxidation. Refrigeration slows all three; freezing a solution introduces a separate risk at the ice interface.

Are the missed weeks in there as blanks or dropped entirely?

Agreed — and the payoff genuinely arrives in month six, not week two.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

fibrosis improvement without worsening steatohepatitis is the phrase to learn

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Asked QYB which lines they hold regionally and got a straight list back. That answered my summer ordering question completely.

the door shelf is the worst place in the fridge

Lyophilisation removes the water that drives most degradation pathways. That is why the dry cake is comparatively robust and the reconstituted solution is not.

Split an order across two months deliberately to compare summer and winter transit on the same lane. Four days difference, same carrier.

light matters more than people think for some of these

Annotated the fortnight I changed training. Without that note the numbers around it would look like a mystery.

if 7.5 is working, 10 is not automatically better

Push back: you cannot infer degradation from a temperature excursion alone. That is what testing is for.

hold the dose that works, the ladder is not a leaderboard

The distribution matters more than the mean.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

zepbound and mounjaro are the same compound with different labels

18kg over 83 weeks, never went past 10mg, and muscle cramps stayed mild the whole way. Posting because the loud threads are all 15mg.

Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 10 is not a fair reading.

Agreed. One line a week that actually gets written beats an elaborate template abandoned in month two.

Week 75 was the first time the scale moved after a five-week stall. I changed nothing in that window.

the early fullness profile is genuinely gentler than people expect coming from sema

Are you reading the publication or a summary?

This is the framing the board needs. It is a hepatic programme first.